Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma

@inproceedings{Semba2014BrimonidinePN,
  title={Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma},
  author={Kentaro Semba and Kazuhiko Namekata and Atsuko Kimura and Chikako Harada and Yoshinori Mitamura and Tatsuya Harada},
  booktitle={Cell Death and Disease},
  year={2014}
}
Glaucoma is one of the leading causes of irreversible blindness that is characterized by progressive degeneration of optic nerves and retinal ganglion cells (RGCs). In the mammalian retina, excitatory amino-acid carrier 1 (EAAC1) is expressed in neural cells, including RGCs, and the loss of EAAC1 leads to RGC degeneration without elevated intraocular pressure (IOP). Brimonidine (BMD) is an α2-adrenergic receptor agonist and it is commonly used in a form of eye drops to lower IOP in glaucoma… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Study of Effects of Antiglaucoma Eye Drops on N-Methyl-d-Aspartate-Induced Retinal Damage

Japanese Journal of Ophthalmology • 2005
View 6 Excerpts
Highly Influenced

Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage.

The Journal of neuroscience : the official journal of the Society for Neuroscience • 1996
View 5 Excerpts
Highly Influenced

The treatment of normal-tension glaucoma.

Progress in brain research • 2008
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…